keyword
MENU ▼
Read by QxMD icon Read
search

Anemia hemodialysis

keyword
https://read.qxmd.com/read/30865950/most-important-prognostic-values-to-predict-major-adverse-cardiovascular-cerebrovascular-and-renal-events-in-patients-with-chronic-kidney-disease-including-hemodialysis-for-2-years
#1
Takuji Toyama, Shu Kasama, Makito Sato, Hirokazu Sano, Tetsuya Ueda, Toyoshi Sasaki, Takehiro Nakahara, Tetsuya Higuchi, Yoshito Tsushima, Masahiko Kurabayashi
Patients with chronic kidney disease (CKD) have an increased risk of adverse cardiovascular/cerebrovascular events. The aim of this study is to clarify whether stress myocardial perfusion single-photon emission computed tomography (SPECT) could predict cardiovascular/cerebrovascular events. In the Gunma-CKD SPECT Study, a multicenter prospective cohort trial, 311 patients with CKD (estimated glomerular filtration rate < 60 min/mL/1.73 m2) including 50 patients on hemodialysis underwent stress 99mTc-tetrofosmin SPECT for suspected ischemic heart disease and were followed for 2 years...
March 13, 2019: Cardiology
https://read.qxmd.com/read/30865300/etoricoxib-induced-immune-hemolytic-anemia-first-case-presenting-acute-kidney-failure
#2
L Burgos Pratx, D Santoro, B Coca Mogro, V L Valiente, P Camino, W Scordo, H Salamone
BACKGROUND: Etoricoxib is a selective inhibitor of cyclooxygenase 2 used mainly to treat osteoarticular pain. Here, we report the case of a patient who developed acute kidney failure and immune hemolytic anemia after the use of etoricoxib. STUDY DESIGN AND METHODS: An 83-year-old female patient developed immune hemolytic anemia and acute kidney failure after treatment with etoricoxib for articular pain. Given the acute kidney failure, she required five hemodialysis sessions...
March 13, 2019: Transfusion
https://read.qxmd.com/read/30852574/long-term-efficacy-and-safety-of-molidustat-for-anemia-in-chronic-kidney-disease-dialogue-extension-studies
#3
Tadao Akizawa, Iain C Macdougall, Jeffrey S Berns, Thomas Bernhardt, Gerald Staedtler, Megumi Taguchi, Kazuma Iekushi, Thilo Krueger
BACKGROUND: Molidustat, a novel hypoxia-inducible factor-prolyl hydroxylase inhibitor, is being investigated for the treatment of anemia associated with chronic kidney disease (CKD). The efficacy and safety of molidustat were recently evaluated in three 16-week phase 2b studies. Here, we report the results of two long-term extension studies of molidustat. METHODS: Both studies were parallel-group, open-label, multicenter studies of ≤36 months' duration, in patients with anemia due to CKD, and included an erythropoiesis-stimulating agent as active control...
March 8, 2019: American Journal of Nephrology
https://read.qxmd.com/read/30827015/a-case-of-biopsy-proven-oxaliplatin-induced-acute-tubulointerstitial-nephritis-with-thrombocytopenia-and-anemia
#4
Shohei Yamada, Masahiko Yazawa, Makoto Yamamoto, Kenichiro Koitabashi, Daisuke Ichikawa, Jyunki Koike, Yugo Shibagaki
Oxaliplatin, a third-generation platinum agent, has been used for the treatment of colon, pancreatic, and stomach cancers in recent years. It carries a reduced risk of acute kidney injury (AKI) compared to the previous platinum agents, including cisplatin and carboplatin. Several cases of oxaliplatin-induced acute tubular necrosis (ATN) have been reported; however, only one case has been reported as acute tubulointerstitial nephritis (ATIN) histopathologically. Here, we present a case of biopsy-proven and dialysis-dependent ATIN, which dramatically resolved with steroid therapy...
March 2, 2019: CEN Case Reports
https://read.qxmd.com/read/30814798/missed-monoclonal-disease-manifesting-in-early-post-renal-transplant-period
#5
N Singh, N Pattanashetti, K Joshi, H S Kohli, K L Gupta, R Ramachandran
A 63-year-old diabetic gentleman with microvascular complications presented with advanced azotemia and anemia. He was stabilized with blood transfusion and hemodialysis. With the probable diagnosis of diabetic nephropathy-related end-stage renal disease, he underwent kidney transplantation. He had delayed graft function. Graft biopsy done on the 2nd postoperative day showed acute tubular necrosis. Graft biopsy repeated after 2 weeks for persistent graft dysfunction showed myeloma cast nephropathy (MCN) and light chain proximal tubulopathy...
January 2019: Indian Journal of Nephrology
https://read.qxmd.com/read/30804267/risk-factors-and-prevalence-of-cardiac-diseases-in-egyptian-pediatric-patients-with-end-stage-renal-disease-on-regular-hemodialysis
#6
Mohamed A El-Gamasy, Wegdan H Mawlana
Cardiac disease is a significant cause of morbidity and mortality in children with end-stage renal disease (ESRD). The aim of this work was to study the risk factors and prevalence of cardiac diseases in Egyptian pediatric patients with ESRD under regular hemodialysis (HD). Sixty-six children with ESRD on regular HD were included and subjected to history, clinical, laboratory, chest X-rays (CXR), ECG, and two-dimensional echocardiographic study to measure different echocardiographic parameters focusing on the left ventricular ejection fraction...
January 2019: Saudi Journal of Kidney Diseases and Transplantation
https://read.qxmd.com/read/30802204/ferumoxytol-for-iron-deficiency-anemia-in-patients-undergoing-hemodialysis-the-fact-randomized-controlled-trial
#7
Iain C Macdougall, William E Strauss, Naomi V Dahl, Kristine Bernard, Zhu Li
BACKGROUND: Patients with chronic kidney disease (CKD) undergoing dialysis often require intravenous iron for iron deficiency anemia (IDA). MATERIALS AND METHODS: The Ferumoxytol for Anemia of CKD Trial (FACT), a randomized, multicenter, open-label, phase 4 study, compared the long-term safety and efficacy of ferumoxytol with iron sucrose for the treatment of IDA in patients with CKD undergoing hemodialysis. Patients with IDA and CKD undergoing hemodialysis were randomized 2:1 to ferumoxytol 1...
February 25, 2019: Clinical Nephrology
https://read.qxmd.com/read/30783915/regional-prescription-surveillance-of-phosphate-binders-in-the-western-saitama-area-the-substantial-role-of-ferric-citrate-hydrate-in-improving-serum-phosphorus-levels-and-erythropoiesis
#8
Hiroaki Amano, Yoichi Ohno, Tsutomu Inoue, Koji Tomori, Kazuya Ohama, Hirokazu Okada
BACKGROUND: In April 2015, five types of phosphate binders (PBs) were available by prescription in Japan, namely calcium carbonate, sevelamer hydrochloride, lanthanum carbonate, bixalomer, and ferric citrate hydrate (FeC). FeC reduces serum phosphorus levels and increases the body's iron stores. However, it is unclear whether FeC lowers serum phosphorus relative to other agents in a regional practical setting. METHODS: We performed a retrospective observational cohort study of regional hemodialysis surveillance in the western Saitama area of Japan, which included 1374 hemodialysis patients enrolled from 32 satellite dialysis units...
February 19, 2019: Clinical and Experimental Nephrology
https://read.qxmd.com/read/30783118/comparing-the-effects-of-intravenous-and-subcutaneous-erythropoietin-on-blood-indices-in-hemodialysis-patients
#9
Faramarz Ghasemi, Alireza Abdi, Nader Salari, Mohammad Reza Tohidi, Aazam Faraji
Erythropoietin is used routinely in hemodialysis patients to increase hemoglobin levels in patients with ESRD and anemia. Considering the importance of anemia in hemodialysis patients and its complications, in this study, the effect of erythropoietin administration on blood parameters by comparing the methods of subcutaneous and intravenous administrations was investigated. The research was done as a retrospective descriptive-analytic study. The subjects were 300 hemodialysis patients receiving erythropoietin in two groups (intravenous and subcutaneous) from hospitals affiliated to Kurdistan and Kermanshah University of Medical Sciences...
February 19, 2019: Scientific Reports
https://read.qxmd.com/read/30778828/ambulatory-blood-pressures-and-central-blood-pressures-are-associated-with-cardiovascular-morbidity-in-adolescent-and-young-adult-patients-receiving-chronic-hemodialysis
#10
Shweta Shah, Sarah Swartz, Jessica Campbell, Poyyapakkam R Srivaths
BACKGROUND: Left ventricular hypertrophy (LVH) and arterial stiffness measured by pulse wave velocity (PWV) are independent predictors of cardiovascular (CV) mortality in adults receiving chronic dialysis. Hypertension strongly associates with elevated left ventricular mass index (LVMI) and PWV, with ambulatory blood pressure monitoring (ABPM), and central blood pressure (CBP) superior to office blood pressures (BP) in predicting CV morbidity. Few studies have described associations of office BP, ABPM, and CBP with LVMI and PWV in adolescent and young adult patients receiving hemodialysis (HD)...
February 18, 2019: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://read.qxmd.com/read/30772880/-off-pump-coronary-artery-bypass-grafting-in-jehovah-s-witness-patient-on-hemodialysis-report-of-a-case
#11
Kae Ito, Motohiro Koyama, Keishi Ueyama
Cardiac surgery in Jehovah's witnesses is challenging due to their refusal of blood transfusion. Furthermore, dialysis patients often suffer from anemia and are also prone to bleeding. We performed offpump coronary artery bypass grafting (CABG) [OPCAB] on a Jehovah's witness male patient on hemodialysis. His preoperative hemoglobin level was around 10.0 g/dl. We used cell saver-collected blood as much as possible during operation. His postoperative course was uneventful with the lowest hemoglobin level of 7...
February 2019: Kyobu Geka. the Japanese Journal of Thoracic Surgery
https://read.qxmd.com/read/30755495/therapeutic-targets-for-the-anemia-of-predialysis-chronic-kidney-disease-a-meta-analysis-of-randomized-controlled-trials
#12
Hongyong Liu, Yuqiu Ye, Yanbing Chen, Yunqiang Zhang, Shaomin Li, Wentao Hu, Rongqian Yang, Zhesi Zhang, Hongquan Peng, Linsheng Lv, Xun Liu
Anemia is one of the major complications in predialysis patients with chronic kidney disease (CKD). A clearer cognition of the prognostic impact of hemoglobin (Hb) or hematocrit (Hct) target on the outcomes of predialysis patients with CKD is significant. This article aims to establish the suitable hemoglobin target to provide clinical guidance. MEDLINE, EmBase, the Cochrane Library and other databases were searched with both MeSH terms and keywords to gather researches that assessed all-cause mortality, stroke, treatment of renal replacement, and transfusion...
February 11, 2019: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://read.qxmd.com/read/30746141/daprodustat-for-anemia-a-24-week-open-label-randomized-controlled-trial-in-participants-on-hemodialysis
#13
Amy M Meadowcroft, Borut Cizman, Louis Holdstock, Nandita Biswas, Brendan M Johnson, Delyth Jones, A Kaldun Nossuli, John J Lepore, Michael Aarup, Alexander R Cobitz
Background: This study evaluated the hemoglobin dose response, other efficacy measures and safety of daprodustat, an orally administered, hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anemia of chronic kidney disease. Methods: Participants ( n  = 216) with baseline hemoglobin levels of 9-11.5 g/dL on hemodialysis (HD) previously receiving stable doses of recombinant human erythropoietin (rhEPO) were randomized in a 24-week dose-range, efficacy and safety study...
February 2019: Clinical Kidney Journal
https://read.qxmd.com/read/30740169/role-of-soluble-transferrin-receptor-and-transferrin-receptor-ferritin-index-to-detect-iron-deficiency-anemia-in-regular-hemodialysis-patients
#14
Ketut Suega, Yenny Kandarini, Jemi Tubung
BACKGROUND: Several iron indicators can be used to detect iron deficiency anaemia (IDA) where confounding comorbidities occurred such as patients with regular hemodialysis. AIM: This study was aimed to determine the diagnostic value of serum transferrin receptor (sTfR) and transferrin receptor-transferrin index (TfR-F index) and to combine these two markers in detecting IDA in regular hemodialysis anaemic patients. METHODS: There were 70 patients recruited consecutively...
January 15, 2019: Open Access Macedonian Journal of Medical Sciences
https://read.qxmd.com/read/30725033/-evolution-of-aplastic-anemia-in-a-patient-on-chronic-hemodialysis-sixteen-years-later%C3%A2
#15
Jorge Vega Stieb
No abstract text is available yet for this article.
September 2018: Revista Médica de Chile
https://read.qxmd.com/read/30698206/restless-legs-syndrome-in-end-stage-renal-disease-patients-undergoing-hemodialysis
#16
Sergio Andrés Castillo-Torres, Héctor Raúl Ibarra-Sifuentes, Helda Sánchez-Terán, Concepción Sánchez-Martínez, Beatriz Chávez-Luévanos, Ingrid Estrada-Bellmann
OBJECTIVES: Restless legs syndrome (RLS) is a frequent complication of hemodialysis that has been associated with poor quality of life and increased risk for complications. Nevertheless, few studies regarding this entity exist in resource-limited settings. To determine the prevalence of RLS among Mexican patients on hemodialysis; and compare these patients with a control group of the same population. METHODS: We recruited 105 hemodialysis patients. Restless legs syndrome was diagnosed according to the updated criteria set out by the International RLS Study Group...
December 2018: Arquivos de Neuro-psiquiatria
https://read.qxmd.com/read/30684305/efficacy-for-anemia-and-changes-in-serum-ferritin-levels-by-long-term-oral-iron-administration-in-hemodialysis-patients
#17
Shoichiro Daimon
Oral iron preparations are useful for the treatment of anemia in hemodialysis patients; however, long-term changes in the iron dynamics and effects of anemia are unknown. Serum ferritin levels and erythropoietin-stimulating agent (ESA)/hemoglobin (Hb) ratios were investigated for 750 days in the following four groups: patients treated with sodium ferrous citrate (SF) (de novo 50 mg/day and 150 mg/day switched from 50 mg/day) and patients treated with 1500 mg/day of ferric citrate (FC) (de novo and switched from 50 mg/day of SF)...
January 25, 2019: Therapeutic Apheresis and Dialysis
https://read.qxmd.com/read/30683605/different-effects-of-iron-indices-on-mortality-in-patients-with-autosomal-dominant-polycystic-kidney-disease-after-long-term-hemodialysis-a-nationwide-population-based-study
#18
Shu-Ching Yeh, Yi-Chun Lin, Ying-Chung Hong, Chih-Cheng Hsu, Yen-Chung Lin, Mai-Szu Wu
OBJECTIVE: Iron supplementation and erythropoietin stimulating agents (ESAs) are essential for maintaining hemoglobin levels in hemodialysis patients. However, patients with autosomal-dominant polycystic kidney disease (PKD) have higher endogenous erythropoietin levels, so their recommended iron indices for hemodialysis patients may differ. This study evaluated iron profiles, including ferritin levels and transferrin saturation (TSAT) to identify factors affecting mortality in patients on dialysis, and those associated with mortality in patients with and without PKD...
January 22, 2019: Journal of Renal Nutrition
https://read.qxmd.com/read/30648029/sub-acute-cardiac-tamponade-as-an-early-clinical-presentation-of-childhood-systemic-lupus-erythematosus-a-case-report
#19
Anum Umer, Shoaib Bhatti, Shafaq Jawed
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple systems by the process of inflammation and formation of auto-antibodies. When it presents in childhood, it is referred to as childhood systemic lupus erythematosus (cSLE). Cardiac tamponade is a rare but potentially lethal complication of cSLE, even rarer as an initial presentation. Sub-acute cardiac tamponade (medical tamponade) is a non-emergent type of cardiac tamponade which develops slowly over time and does not necessarily present with acute distress...
October 22, 2018: Curēus
https://read.qxmd.com/read/30639044/-short-term-effects-with-sucroferric-oxyhydroxide-in-hemodialysis-patients-experience-in-nephrocare-france
#20
Charles Chazot, Baya Fadel, Mimi Kareche, Olivier Puyoo, Guillaume Jean
INTRODUCTION: Despite a better management of hyperphosphatemia in haemodialysis patients observed during the past years, most of them remain insufficiently treated and exposed to bone and cardiovascular complications that are associated with this biological abnormality. The availability of calcium-free phosphate binders among therapeutical options is confirmed to significantly reduce serum phosphate levels without the risk of excess exposure to calcium. Currently sucroferric oxyhydroxyde (SO) is the only iron-based phosphate binder available in France...
January 10, 2019: Néphrologie & Thérapeutique
keyword
keyword
160541
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"